**FOI Ref: 6615**

**Category(ies): Clinical - Drugs**

**Subject: Biologic Medicines in Dermatology**

**Date Received: 20/09/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| I have a freedom of information query regarding the use of Biologic medicines in Dermatology.  Could you please answer the following two questions: |
| 1. How many patients were treated in the last 3 months by the **Dermatology** department (for any medical condition) with the following biologic drugs:
* Abatacept
* Adalimumab - Humira
* Adalimumab Biosimilar
* Apremilast
* Bimekizumab
* Brodalumab
* Certolizumab
* Dimethyl fumarate
* Etanercept - Enbrel
* Etanercept Biosimilar
* Golimumab
* Guselkumab
* Infliximab - Remicade
* Infliximab Biosimilar
* Ixekizumab
* Risankizumab
* Secukinumab
* Tildrakizumab
* Tofacitinib
* Ustekinumab
* Upadacitinib
 | * Abatacept – 0
* Adalimumab – Humira – 0
* Adalimumab Biosimilar – 32
* Apremilast – 0
* Bimekizumab – 0
* Brodalumab – 2
* Certolizumab – 3
* Dimethyl fumarate – 2
* Etanercept – Enbrel – 0
* Etanercept Biosimilar – 0
* Golimumab – 0
* Guselkumab – 29
* Infliximab – Remicade – 0
* Infliximab Biosimilar – 0
* Ixekizumab – 3
* Risankizumab – 13
* Secukinumab – 25
* Tildrakizumab – 0
* Tofacitinib – 0
* Ustekinumab – 34
* Upadacitinib – 0
 |
| 1. How many patients were treated in the last 3 months by the **Dermatology** department for Psoriatic Arthritis (PsA) ONLY with the following biologic drugs:
* Adalimumab - Humira
* Adalimumab Biosimilar
* Apremilast
* Certolizumab
* Dimethyl fumarate
* Etanercept - Enbrel
* Etanercept Biosimilar
* Guselkumab
* Infliximab - Remicade
* Infliximab Biosimilar
* Ixekizumab
* Risankizumab
* Secukinumab
* Ustekinumab
 | We don’t keep data of psoriatic arthritis only so are unable to provide data for this. |